JNJ Valuation Tops 37% Above GF Value Amid Promising Cancer Treatment Results
Johnson & Johnson (JNJ) announced promising results from its Phase 2b COPERNICUS study, demonstrating the benefits of less frequent dosing with RYBREVANT FASPRO and LAZCLUZE for untreated advanced non-small cell lung cancer patients with common EGFR mutations. The regimen showed minimal adverse effects and a treatment discontinuation rate below 1% within a year.
The company's strong dividend sustainability remains a key feature, with a current yield of 1.95%, a payout ratio of just 50%, and a steady 3-year dividend growth rate of 4.9%. However, the stock's valuation presents a cautionary note, with its GF Value at $193.37, which is 37.7% below the current market price of $266.32.
GuruFocus' GF Score gives JNJ an impressive 83 out of 100, reflecting strong financial health, profitability, and growth prospects. However, insider activity shows significant net selling over the past 12 months, while the stock's trailing P/E ratio is elevated compared to its 5-year median.